|
gptkbp:instanceOf
|
gptkb:drug
opioid
|
|
gptkbp:activeIngredient
|
gptkb:morphine
|
|
gptkbp:affiliatedWith
|
phenanthrenes
natural opiates
|
|
gptkbp:antidote
|
gptkb:naloxone
|
|
gptkbp:approvalYear
|
1941
|
|
gptkbp:approvedBy
|
US
|
|
gptkbp:ATCCode
|
N02AA01
|
|
gptkbp:bioavailability
|
20-40% (oral)
|
|
gptkbp:brand
|
gptkb:Duramorph
gptkb:Roxanol
gptkb:MS_Contin
gptkb:Avinza
gptkb:Kadian
|
|
gptkbp:CASNumber
|
6211-15-0
|
|
gptkbp:contraindication
|
respiratory depression
acute asthma
paralytic ileus
|
|
gptkbp:controlledSubstanceSchedule
|
gptkb:Schedule_II_(US)
|
|
gptkbp:discoveredBy
|
gptkb:Friedrich_Sertürner
|
|
gptkbp:discoveredIn
|
1804
|
|
gptkbp:eliminationHalfLife
|
2-4 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:halfLife
|
2-4 hours (immediate release)
8-12 hours (extended release)
|
|
gptkbp:hasMolecularFormula
|
C34H40N2O10S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
morphine sulfate
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
mu-opioid receptor agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
30-35%
|
|
gptkbp:riskFactor
|
addiction
tolerance
dependence
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
constipation
drowsiness
respiratory depression
|
|
gptkbp:usedFor
|
pain management
chronic pain
acute pain
|
|
gptkbp:bfsParent
|
gptkb:Duramorph
gptkb:Roxanol
gptkb:Sevredol
gptkb:MSIR
gptkb:MS_Contin
gptkb:Avinza
gptkb:Kadian
gptkb:Oramorph
|
|
gptkbp:bfsLayer
|
7
|